Skip to Main Content
S. Karger AG
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 13, Issue 3
June 2024
Issue Cover
All Issues
ISSN 2235-1795
EISSN 1664-5553
In this Issue

Liver Cancer 2024, Vol. 13, No. 3

Editorial

Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
Subject Area: Gastroenterology , Oncology
Masatoshi Kudo
Liver Cancer (2024) 13 (3): 227–234. https://doi.org/10.1159/000538558
View articletitled, Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
Open the PDF for in another window

Meta-Analysis

Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis
Subject Area: Gastroenterology , Oncology
Andrea Pasta; Francesco Calabrese; Ariel Jaffe; Sara Labanca; Simona Marenco; Giulia Pieri; Maria Corina Plaz Torres; Mario Strazzabosco; Edoardo G. Giannini
Liver Cancer (2024) 13 (3): 235–245. https://doi.org/10.1159/000533991
View articletitled, Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis
Open the PDF for in another window

Review Article

Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
Subject Area: Gastroenterology , Oncology
Sang Youn Hwang; Sangjune L. Lee; Hongqun Liu; Samuel S. Lee
Liver Cancer (2024) 13 (3): 246–255. https://doi.org/10.1159/000534303
View articletitled, Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
Open the PDF for in another window

Research Article

PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Subject Area: Gastroenterology , Oncology
Ghassan K. Abou-Alfa; Peter R. Galle; Yee Chao; Joseph Erinjeri; Jeong Heo; Mitesh J. Borad; Angelo Luca; James Burke; Adina Pelusio; Delphine Agathon; Monika Lusky; Caroline Breitbach; Shukui Qin; Edward Gane
Liver Cancer (2024) 13 (3): 256–272. https://doi.org/10.1159/000533650
View articletitled, PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Open the PDF for in another window
Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma
Subject Area: Gastroenterology , Oncology
Chi Leung Chiang; Francis Ann Shing Lee; Kenneth Sik Kwan Chan; Venus Wan Yan Lee; Keith Wan Hang Chiu; Ryan Lok Man Ho; John Ka Shun Fong; Natalie Sean Man Wong; Winnie Wing Ling Yip; Cynthia Sin Yu Yeung; Vince Wing Hang Lau; Kwan Man; Feng-Ming Spring Kong; Albert Chi Yan Chan
Liver Cancer (2024) 13 (3): 273–284. https://doi.org/10.1159/000533425
View articletitled, Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma
Open the PDF for in another window
Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study
Subject Area: Gastroenterology , Oncology
Yu Ki Sim; Ming Chuen Chong; Mihir Gandhi; Yogesh Mahadev Pokharkar; Yanan Zhu; Luming Shi; Li Lequn; Chien-Hung Chen; Masatoshi Kudo; Joon Hyeok Lee; Simone I. Strasser; Rawisak Chanwat; Pierce K.H. Chow; on behalf of the Asia-Pacific Hepatocellular Carcinoma Trials Group
Liver Cancer (2024) 13 (3): 306–321. https://doi.org/10.1159/000534513
View articletitled, Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study
Open the PDF for in another window
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial)
Subject Area: Gastroenterology , Oncology
Akihiko Ichida; Junichi Arita; Etsuro Hatano; Susumu Eguchi; Akio Saiura; Hiroaki Nagano; Junichi Shindoh; Masaji Hashimoto; Nobuyuki Takemura; Kojiro Taura; Yoshihiro Sakamoto; Yu Takahashi; Yasuji Seyama; Yasuharu Sasaki; Kohei Uemura; Norihiro Kokudo; Kiyoshi Hasegawa
Liver Cancer (2024) 13 (3): 322–334. https://doi.org/10.1159/000535514
View articletitled, A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial)
Open the PDF for in another window
High frequency of CTNNB1 variants associated with benign and malignant liver tumors in patients with Congenital Porto-Systemic Shunts
Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Contents Vol. 13, 2024
  • Online ISSN 1664-5553
  • Print ISSN 2235-1795
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal